{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T18:10:27Z","timestamp":1793038227178,"version":"4.5.0"},"reference-count":29,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","license":[{"start":{"date-parts":[[2017,5,1]],"date-time":"2017-05-01T00:00:00Z","timestamp":1493596800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["jurology.com","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Urology"],"published-print":{"date-parts":[[2017,5]]},"DOI":"10.1016\/j.juro.2016.12.022","type":"journal-article","created":{"date-parts":[[2016,12,16]],"date-time":"2016-12-16T22:31:48Z","timestamp":1481927508000},"page":"1251-1257","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"title":["Risks of Serious Toxicities from Intermittent versus Continuous Androgen Deprivation Therapy for Advanced Prostate Cancer: A Population Based Study"],"prefix":"10.1097","volume":"197","author":[{"given":"Huei-Ting","family":"Tsai","sequence":"first","affiliation":[{"name":"Cancer Prevention and Control Program, Lombardi Comprehensive Cancer Center, Department of Oncology, Georgetown University Medical Center, Georgetown University, Washington, D.C."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth M.","family":"Pfeiffer","sequence":"additional","affiliation":[{"name":"National Cancer Institute, National Institutes of Health, Bethesda, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George K.","family":"Philips","sequence":"additional","affiliation":[{"name":"Department of Medicine, Georgetown University Medical Center, Georgetown University, Washington, D.C."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Barac","sequence":"additional","affiliation":[{"name":"Division of Cardiology, MedStar Washington Hospital Center, Washington, D.C."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex Z.","family":"Fu","sequence":"additional","affiliation":[{"name":"Cancer Prevention and Control Program, Lombardi Comprehensive Cancer Center, Department of Oncology, Georgetown University Medical Center, Georgetown University, Washington, D.C."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David F.","family":"Penson","sequence":"additional","affiliation":[{"name":"Department of Urologic Surgery, Vanderbilt University Medical Center, Nashville, Tennessee"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingjun","family":"Zhou","sequence":"additional","affiliation":[{"name":"Cancer Prevention and Control Program, Lombardi Comprehensive Cancer Center, Department of Oncology, Georgetown University Medical Center, Georgetown University, Washington, D.C."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnold L.","family":"Potosky","sequence":"additional","affiliation":[{"name":"Cancer Prevention and Control Program, Lombardi Comprehensive Cancer Center, Department of Oncology, Georgetown University Medical Center, Georgetown University, Washington, D.C."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"10.1016\/j.juro.2016.12.022_bib1","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1007\/s11934-011-0178-0","article-title":"Androgen suppression strategies for prostate cancer: is there an ideal approach?","volume":"12","author":"Ismail","year":"2011","journal-title":"Curr Urol Rep"},{"key":"10.1016\/j.juro.2016.12.022_bib2","doi-asserted-by":"crossref","first-page":"e119","DOI":"10.1097\/01.coc.0000091351.09243.15","article-title":"Intermittent androgen deprivation for patients with recurrent\/metastatic prostate cancer","volume":"26","author":"Youssef","year":"2003","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.juro.2016.12.022_bib3","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/nrurol.2009.237","article-title":"Treatment strategies for high-risk locally advanced prostate cancer","volume":"7","author":"Rosenthal","year":"2010","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.juro.2016.12.022_bib4","doi-asserted-by":"crossref","first-page":"3452","DOI":"10.1200\/JCO.2008.20.0923","article-title":"Impact of androgen deprivation therapy on cardiovascular disease and diabetes","volume":"27","author":"Alibhai","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.juro.2016.12.022_bib5","doi-asserted-by":"crossref","first-page":"4448","DOI":"10.1200\/JCO.2006.06.2497","article-title":"Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer","volume":"24","author":"Keating","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.juro.2016.12.022_bib6","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1161\/CIRCULATIONAHA.109.192695","article-title":"Androgen-deprivation therapy in prostate cancer and cardiovascular risk: a science advisory from the American Heart Association, American Cancer Society, and American Urological Association: endorsed by the American Society for Radiation Oncology","volume":"121","author":"Levine","year":"2010","journal-title":"Circulation"},{"key":"10.1016\/j.juro.2016.12.022_bib7","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1001\/jama.2009.1137","article-title":"Hormonal therapy use for prostate cancer and mortality in men with coronary artery disease-induced congestive heart failure or myocardial infarction","volume":"302","author":"Nanda","year":"2009","journal-title":"JAMA"},{"key":"10.1016\/j.juro.2016.12.022_bib8","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1056\/NEJMoa041943","article-title":"Risk of fracture after androgen deprivation for prostate cancer","volume":"352","author":"Shahinian","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.juro.2016.12.022_bib9","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.eururo.2014.11.039","article-title":"Quantifying observational evidence for risk of fatal and nonfatal cardiovascular disease following androgen deprivation therapy for prostate cancer: a meta-analysis","volume":"68","author":"Bosco","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.juro.2016.12.022_bib10","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1016\/j.eururo.2013.02.002","article-title":"Androgen-deprivation therapy in treatment of prostate cancer and risk of myocardial infarction and stroke: a nationwide Danish population-based cohort study","volume":"65","author":"Jespersen","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.juro.2016.12.022_bib11","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1093\/jnci\/djm168","article-title":"Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality","volume":"99","author":"Tsai","year":"2007","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.juro.2016.12.022_bib12","doi-asserted-by":"crossref","first-page":"3448","DOI":"10.1200\/JCO.2010.29.1567","article-title":"Absolute and relative risk of cardiovascular disease in men with prostate cancer: results from the Population-Based PCBaSe Sweden","volume":"28","author":"Van Hemelrijck","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.juro.2016.12.022_bib13","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1056\/NEJMoa1201546","article-title":"Intermittent androgen suppression for rising PSA level after radiotherapy","volume":"367","author":"Crook","year":"2012","journal-title":"N Engl J Med"},{"issue":"suppl.","key":"10.1016\/j.juro.2016.12.022_bib14","doi-asserted-by":"crossref","first-page":"5015","DOI":"10.1200\/jco.2007.25.18_suppl.5015","article-title":"Randomised prospective study of intermittent versus continuous androgen suppression in advanced prostate cancer","volume":"25","author":"Miller","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.juro.2016.12.022_bib15","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1001\/jamaoncol.2015.2895","article-title":"Intermittent vs continuous androgen deprivation therapy for prostate cancer: a systematic review and meta-analysis","volume":"1","author":"Magnan","year":"2015","journal-title":"JAMA Oncol"},{"issue":"suppl.","key":"10.1016\/j.juro.2016.12.022_bib16","first-page":"IV","article-title":"Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population","volume":"40","author":"Warren","year":"2002","journal-title":"Med Care"},{"key":"10.1016\/j.juro.2016.12.022_bib17","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.urpr.2014.11.001","article-title":"Adoption of intermittent androgen deprivation therapy for advanced prostate cancer: a population based study in American urology practice","volume":"2","author":"Tsai","year":"2015","journal-title":"Urol Pract"},{"key":"10.1016\/j.juro.2016.12.022_bib18","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.urology.2013.01.078","article-title":"Efficacy of intermittent androgen deprivation therapy vs conventional continuous androgen deprivation therapy for advanced prostate cancer: a meta-analysis","volume":"82","author":"Tsai","year":"2013","journal-title":"Urology"},{"key":"10.1016\/j.juro.2016.12.022_bib19","unstructured":"PROMIS\u00ae. Northwestern University 2016. Available at http:\/\/www.healthmeasures.net\/explore-measurement-systems\/promis. Accessed September 1, 2016."},{"key":"10.1016\/j.juro.2016.12.022_bib20","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1001\/jamaoncol.2015.4655","article-title":"Adverse health events following intermittent and continuous androgen deprivation in patients with metastatic prostate cancer","volume":"2","author":"Hershman","year":"2016","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.juro.2016.12.022_bib21","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.cger.2009.07.007","article-title":"The burden of cardiovascular disease in the elderly: morbidity, mortality, and costs","volume":"25","author":"Yazdanyar","year":"2009","journal-title":"Clin Geriatr Med"},{"key":"10.1016\/j.juro.2016.12.022_bib22","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1177\/1756287215617872","article-title":"Androgen deprivation therapy and cardiovascular disease: what is the linking mechanism?","volume":"8","author":"Zareba","year":"2016","journal-title":"Ther Adv Urol"},{"key":"10.1016\/j.juro.2016.12.022_bib23","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.urolonc.2015.05.030","article-title":"Cardiovascular risk with androgen deprivation therapy for prostate cancer: potential mechanisms","volume":"33","author":"Tivesten","year":"2015","journal-title":"Urol Oncol"},{"key":"10.1016\/j.juro.2016.12.022_bib24","doi-asserted-by":"crossref","first-page":"e147","DOI":"10.1016\/j.jacc.2013.05.019","article-title":"2013 ACCF\/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines","volume":"62","author":"Yancy","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.juro.2016.12.022_bib25","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.jacc.2015.12.005","article-title":"Testosterone and cardiovascular disease","volume":"67","author":"Kloner","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.juro.2016.12.022_bib26","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s13293-015-0027-9","article-title":"Testosterone modulates cardiac contraction and calcium homeostasis: cellular and molecular mechanisms","volume":"6","author":"Ayaz","year":"2015","journal-title":"Biol Sex Differ"},{"key":"10.1016\/j.juro.2016.12.022_bib27","doi-asserted-by":"crossref","first-page":"R1","DOI":"10.1530\/JOE-15-0518","article-title":"Androgen receptor (AR) in cardiovascular diseases","volume":"229","author":"Huang","year":"2016","journal-title":"J\u00a0Endocrinol"},{"key":"10.1016\/j.juro.2016.12.022_bib28","first-page":"276","article-title":"Effect of androgen suppression on bone mineral density in patients with prostate cancer","volume":"36","author":"Chernichenko","year":"2014","journal-title":"Exp Oncol"},{"key":"10.1016\/j.juro.2016.12.022_bib29","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1200\/JCO.2011.38.3745","article-title":"Long-term dynamics of bone mineral density during intermittent androgen deprivation for men with nonmetastatic, hormone-sensitive prostate cancer","volume":"30","author":"Yu","year":"2012","journal-title":"J\u00a0Clin Oncol"}],"container-title":["Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022534716319541?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022534716319541?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.jurology.com\/doi\/pdf\/10.1016\/j.juro.2016.12.022","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,29]],"date-time":"2022-04-29T04:31:47Z","timestamp":1651206707000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jurology.com\/doi\/10.1016\/j.juro.2016.12.022"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5]]},"references-count":29,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2017,5]]}},"alternative-id":["10.1016\/j.juro.2016.12.022"],"URL":"https:\/\/doi.org\/10.1016\/j.juro.2016.12.022","relation":{},"ISSN":["0022-5347","1527-3792"],"issn-type":[{"value":"0022-5347","type":"print"},{"value":"1527-3792","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Risks of Serious Toxicities from Intermittent versus Continuous Androgen Deprivation Therapy for Advanced Prostate Cancer: A Population Based Study","name":"articletitle","label":"Article Title"},{"value":"The Journal of Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.juro.2016.12.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 by AMERICAN UROLOGICAL ASSOCIATION EDUCATION AND RESEARCH, INC.","name":"copyright","label":"Copyright"}]}}